Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;44(3):e432234.
doi: 10.1200/EDBK_432234.

Immunotherapy in Sarcoma: Current Data and Promising Strategies

Georgina E Wood  1 , Christian Meyer  2 , Florent Petitprez  3 , Sandra P D'Angelo  4
Affiliations
Free article
Review

Immunotherapy in Sarcoma: Current Data and Promising Strategies

Georgina E Wood et al. Am Soc Clin Oncol Educ Book. 2024 Jun.
Free article

Abstract

Traditionally sarcomas have been considered immunologically quiet tumours, with low tumour mutational burden (TMB) and an immunosuppressive tumour microenvironment (TME), consisting of decreased T-cell infiltration and elevated levels of H1F1α, macrophages and neutrophils.1,2 However, research has shown that a subset of sarcomas are immunologically 'hot' with either high TMB, PDL-1 expression, CD8+ T cells or presence of tertiary lymphoid structures (TLS) demonstrating sensitivity to immunotherapy.3,4 Here, we review the current evidence for immunotherapy use in bone sarcomas (BS) and soft tissue sarcomas (STS), with immune checkpoint inhibitors (ICI) and adoptive cellular therapies including engineered T-cell therapies, chimeric antigen receptor (CAR) T-cell therapies, tumour infiltrating lymphocytes (TILs) and cancer vaccines and biomarkers of response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

Substances